Let's talk medical research

Chronic kidney disease (CKD) is one of the top-ten causes of death in the United States – but 96% of people in its early stages don't even know they have it.

With medicine getting ever more targeted and precise, clinical trial protocols are becoming more complex than ever before. While this allows for appropriate evaluation of potential treatment options, it also means that finding patients to take part in trials is increasingly challenging, and the need to look beyond traditional methods of recruitment has become clear.

During a Q3 2018 survey conducted by Antidote Technologies and SCORR Marketing, we explored specific participation stimuli to determine what could make patients consider participating in a clinical trial – and how these motivations varied by condition area.

There are conferences we attend to connect with clients. There are conferences we attend to build partnerships. At SCOPE, we are able to do both. The SCOPE Summit convenes the best, the brightest, and the most dedicated in the clinical trial operations space with one aim: to accelerate clinical research. This is why we go to SCOPE.

Pulmonary hypertension (PH) is a type of high blood pressure in the lungs. A rare disease, PH is often misdiagnosed as asthma or COPD. Unfortunately, delays in diagnosis mean delays in treatment; sometimes, patients aren't diagnosed until they're in late stage disease – and by then, they have limited options.

Despite decades of research, heart disease continues to be the leading cause of death for both men and women in the United States. It’s clear that tackling cardiovascular disease requires a new approach. That’s why today, researchers and heart health advocates are taking on heart disease, stroke, and other conditions from a variety of angles, from exploring precision medicine to driving clinical ...

If you're considering joining a clinical trial, chances are you're also familiar with the common reasons patients choose not to participate.

At Antidote, our goal is to empower patients to connect with research and seek out the best treatments while learning more about their condition. Backpack Health, our newest partner, shares our mission and gives patients a way to lighten the load of living with a chronic disease in a simple, tangible way while connecting patients with research opportunities.

Once a year, we head to Orlando to collaborate with and learn from some of the best and brightest minds in clinical trial operations. That’s right: we’re attending the SCOPE Summit next week.

Hemophilia is a rare genetic bleeding disorder, affecting around 20,000 people in the U.S. Most cases of hemophilia are inherited, but for about 30% of patients, it's caused by a spontaneous mutation in a gene associated with blood clotting.